source
- Gilead reports modest sales rise but analysts question future growth beyond HIV drugsGilead's second‑quarter results showed total product revenue of $7.6 billion, up 8% year‑over‑year. The company's two leading HIV treatments, Biktarvy and Descovy, together generated about $5.7 bi…
- Moderna begins early-stage trial of mRNA Ebola vaccineModerna announced the launch of an early-phase clinical trial testing an mRNA vaccine designed to protect against Ebola virus. The study will enroll healthy volunteers to evaluate the vaccine's saf…